US Merck Beefs up Animal Health With Antelliq Buy

US Merck Beefs up Animal Health with Antelliq Buy (c) Antelliq
US Merck Beefs up Animal Health with Antelliq Buy (c) Antelliq

Merck & Co has agreed to acquire French animal health company Antelliq for a cash payment of about €2.1 billion. Upon completion of the deal, expected in the second quarter of 2019, Antelliq will be a wholly owned and separately operated subsidiary within the US drugmaker’s Animal Health Division.

Vitré, Brittany-based Antelliq is majority controlled by funds advised by private equity group BC Partners, with significant minority interests held by PSP Investments and Pictet. It posted sales of €360 million in the year ending Sept. 30 2018.

The French firm designs and manufactures digital animal identification, traceability and monitoring technologies for livestock and pets, which it says is the fastest growing part of the animal health industry. The digital products are said to provide real-time actionable information to help farmers and veterinarians improve livestock management and health outcomes as well as assisting owners in enhancing their pets’ quality of life.

“The animal health industry is rapidly evolving with revolutionary digital solutions to manage the health and well-being of livestock and companion animals,” said Rick DeLuca, president of Merck Animal Health. “Animal identification, animal monitoring and smart data management are critical components of this transformative technology. This acquisition represents yet another way that we will ensure our place as a leader in animal health, with a substantial and sustainable position, including the most innovative, technological solutions to serve our customers.”

Company

Logo:

Merck & Co

126 East Lincoln Avenue
07065 Rahway
US

Company contact







Special Issue

Circular Plastics Economy
Explore the Future of Plastics

Circular Plastics Economy

This special CHEManager issue explores the industry’s pivotal shift towards a more sustainable, circular plastics value chain. Readers will find expert analysis and real-world solutions for today’s most pressing recycling and regulatory challenges.

Interview

Stability in Motion
Strategic Response to a Shifting Pharma Landscape

Stability in Motion

Stefan Oelrich, Member of the Board of Management and President Pharmaceuticals, Bayer, discusses navigating external volatility, reshaping its internal structures, and investing in future-ready capabilities to ensure sustainable growth.

most read

Photo
28.07.2025 • NewsChemistry

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.